A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-25
DOI
10.1038/s41467-020-15318-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
- (2019) Lu Yang et al. Science Translational Medicine
- SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
- (2018) James W Peacock et al. EMBO Molecular Medicine
- Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes
- (2017) Ashley M. Jacobi et al. METHODS
- Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
- (2016) Xuewen Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis
- (2015) Bin-Zhi Qian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
- (2015) L. R. Kong et al. MOLECULAR CANCER THERAPEUTICS
- A global reference for human genetic variation
- (2015) Richard A. Gibbs et al. NATURE
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
- (2014) B. Besse et al. ANNALS OF ONCOLOGY
- HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
- (2014) Netanya I. Pollock et al. CLINICAL CANCER RESEARCH
- HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer
- (2014) Parul Gupta et al. Molecular Oncology
- Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures
- (2014) Baoping Guo et al. PLoS One
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis
- (2013) Jiunn-Min Shieh et al. International Journal of Medical Sciences
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
- (2009) S. Krishnaswamy et al. CLINICAL CANCER RESEARCH
- Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
- (2008) Katsuhiro Okuda et al. CANCER SCIENCE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now